Study of Programmed Death Ligand 1 and EGFR/HER2 Expression in Non-Small-Cell Lung Carcinoma With a Clinicopathological Spectrum.
epidermal growth factor receptor
her-2-neu
immunohistochemistry
non small cell lung carcinoma
programmed death ligand-1
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
accepted:
05
07
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
10
8
2021
Statut:
epublish
Résumé
Non-small-cell lung carcinoma (NSCLC) is a disease characterized by the upregulation of programmed death ligand 1 (PD-L1) along with alterations in epidermal growth factor receptor (EGFR) and HER2-neu (HER2) amplification in addition to EGFR mutation. In the present study, the expression of PD-L1 and EGFR and HER2-neu in NSCLC was studied and their expression in relation to various clinicopathological parameters was analysed. We studied 49 core biopsy specimens of NSCLC for PD-L1, EGFR and HER2-neu expressions using immunohistochemistry. Scoring was based on the intensity and percentage of tumour cells expressing the immunomarkers. PD-L1, EGFR and HER2-neu expression was seen in 20.4%, 32.7% and 14.2% of NSCLC, respectively. The analysis showed no significant difference in PD-L1 expression in relation to any clinicopathological parameters. Low or negative EGFR expression was significantly associated with positive lymph node status (P=0.04). HER2-neu expression showed a significant difference in relation to tumour histology (adenocarcinoma; P=0.01). Also, there was no difference noted with PD-L1 expression in relation to EGFR and HER2-neu expression. As our study has a small number of cases, the validation of the predictive and prognostic value of these markers in lung cancer patients requires further studies.
Identifiants
pubmed: 34367799
doi: 10.7759/cureus.16195
pmc: PMC8336965
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e16195Informations de copyright
Copyright © 2021, Laishram et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Ann Diagn Pathol. 2019 Aug;41:24-37
pubmed: 31132649
Anticancer Res. 2011 Dec;31(12):4631-6
pubmed: 22199341
Oncol Lett. 2017 Feb;13(2):912-920
pubmed: 28356978
Annu Rev Pathol. 2011;6:49-69
pubmed: 20887192
Pharmacol Ther. 1999 May-Jun;82(2-3):241-50
pubmed: 10454201
Adv Ther. 2019 Aug;36(8):2161-2166
pubmed: 31154630
PLoS One. 2015 Aug 27;10(8):e0136023
pubmed: 26313362
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Thorac Oncol. 2010 Dec;5(12):1922-32
pubmed: 21155183
Cancer Immunol Immunother. 2017 Jul;66(7):865-876
pubmed: 28341875
J Thorac Dis. 2010 Mar;2(1):48-51
pubmed: 22263017
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3645-52
pubmed: 14506153
Expert Rev Anticancer Ther. 2013 Oct;13(10):1219-28
pubmed: 24134423
Sci Rep. 2017 Aug 31;7(1):10255
pubmed: 28860576
Target Oncol. 2017 Oct;12(5):563-569
pubmed: 28624922
J Mol Diagn. 2008 May;10(3):242-8
pubmed: 18403609
J Thorac Oncol. 2016 Jul;11(7):964-75
pubmed: 27117833
BMC Cancer. 2007 Jul 13;7:128
pubmed: 17626639
J Thorac Oncol. 2015 Jun;10(6):910-23
pubmed: 25658629
Oncol Rep. 2000 May-Jun;7(3):603-7
pubmed: 10767376
Indian J Surg Oncol. 2021 Apr;12(Suppl 1):144-151
pubmed: 33994740
Lung Cancer. 2013 Nov;82(2):231-7
pubmed: 23972450
Ann Oncol. 2004 Jan;15(1):28-32
pubmed: 14679115
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Thorac Oncol. 2012 Jan;7(1):122-7
pubmed: 21892099